2020 Announcements

CLINUVEL
Posted by CLINUVEL
October 28, 2020

Afamelanotide for Acute Stroke Patients

EXECUTIVE SUMMARY • World’s first pilot study (CUV801) to evaluate afamelanotide in...

Read More
CLINUVEL
Posted by CLINUVEL
October 27, 2020

Australian TGA approves SCENESSE®

Executive summary SCENESSE® approved by Australian TGA under Priority Review First approved...

Read More
CLINUVEL
Posted by CLINUVEL
October 26, 2020

Update: SCENESSE® in DNA Repair

CLINUVEL PHARMACEUTICALS LTD provided today a clinical update on the use of...

Read More
CLINUVEL
Posted by CLINUVEL
October 26, 2020
CLINUVEL
Posted by CLINUVEL
October 14, 2020

Further Research Coverage Initiated on CLINUVEL

CLINUVEL PHARMACEUTICALS LTD today informed its shareholders and interested investors that Jefferies...

Read More
CLINUVEL
Posted by CLINUVEL
October 9, 2020
CLINUVEL
Posted by CLINUVEL
October 9, 2020

Appendix 4G and Corporate Governance Statement

Download Appendix 4G and Corporate Governance Statement

Read More
CLINUVEL
Posted by CLINUVEL
October 9, 2020

CLINUVEL Annual General Meeting 2020

CLINUVEL PHARMACEUTICALS LTD’s 2020 Annual General Meeting (AGM) will be held on...

Read More
CLINUVEL
Posted by CLINUVEL
October 9, 2020
CLINUVEL
Posted by CLINUVEL
October 7, 2020

SCIENTIFIC COMMUNIQUÉ VI

Ultraviolet Radiation Damage and Oxidative Stress in Skin Cancer. October 2020 Introduction...

Read More
CLINUVEL
Posted by CLINUVEL
September 28, 2020

Kommuniqué V, 20-23 September 2020

Liebe Aktionäre, Freunde,   Während die Welt darum kämpft, die Verbreitung von...

Read More
CLINUVEL
Posted by CLINUVEL
September 23, 2020

CLINUVEL Newsletter V

Dear shareholders, friends,   As the world battles on to control the...

Read More
CLINUVEL
Posted by CLINUVEL
September 23, 2020

CLINUVEL CONFIRMS AGM DATE

Melbourne, Australia, 23 September 2020 CLINUVEL PHARMACEUTICALS LTD today announces it will...

Read More
CLINUVEL
Posted by CLINUVEL
September 16, 2020
We use cookies to give you the best experience.